Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00594308 · OUTCOME

Number of Patients With Acute Grade II-IV GVHD

In-Vivo Activated T-Cell Depletion to Prevent GVHD · Source last updated 2014-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
until 30 days after stem cell transplant

What was measured

Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.

Analysis population: All patient that received study drug

Groups in this outcome

Basiliximab 20 mg

All patients that received Basiliximab 20 mg monoclonal therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Basiliximab 20 mg10

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Basiliximab 20 mg10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.
groups
  1. description
    All patients that received Basiliximab 20 mg monoclonal therapy
    id
    OG000
    title
    Basiliximab 20 mg
param Type
NUMBER
population Description
All patient that received study drug
time Frame
until 30 days after stem cell transplant
title
Number of Patients With Acute Grade II-IV GVHD
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice